Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Front Endocrinol (Lausanne). 2024 Jul 11;15:1400869. doi: 10.3389/fendo.2024.1400869. eCollection 2024.
Thyroid-associated ophthalmopathy (TAO) is an autoimmune condition affecting the eyes, characterized by proptosis, extraocular muscle involvement, and in severe cases, vision impairment including diplopia, optic neuropathy, and potential blindness. The exact etiology of TAO remains elusive; however, increased oxidative stress and decreased antioxidant capacity are pivotal in its pathogenesis. Elevated oxidative stress not only directly damages orbital tissues but also influences thyroid function and autoimmune responses, exacerbating tissue destruction. This review explores the role of oxidative stress in TAO, elucidates its mechanisms, and evaluates the efficacy and limitations of antioxidant therapies in managing TAO. The findings aim to enhance understanding of oxidative stress mechanisms in TAO and propose potential antioxidant strategies for future therapeutic development.
甲状腺相关眼病(TAO)是一种影响眼睛的自身免疫性疾病,其特征是眼球突出、眼外肌受累,在严重情况下,还会导致视力损害,包括复视、视神经病变和潜在失明。TAO 的确切病因仍不清楚;然而,氧化应激的增加和抗氧化能力的降低在其发病机制中起着关键作用。氧化应激的增加不仅直接损害眼眶组织,还影响甲状腺功能和自身免疫反应,从而加剧组织破坏。本综述探讨了氧化应激在 TAO 中的作用,阐明了其机制,并评估了抗氧化治疗在 TAO 管理中的疗效和局限性。这些发现旨在增强对 TAO 中氧化应激机制的理解,并为未来的治疗发展提出潜在的抗氧化策略。